Olink® Target 48 Immune Surveillance Panel – The Next Frontier in Immune Biomarker Profiling with Absolute Confidence
Olink Holding AB (Nasdaq: OLK) has launched the Olink Target 48 Immune Surveillance panel. This validated multiplexed protein assay panel provides an in-depth analysis of the immune system, monitoring inflammation and immune response using only 1μL of sample. When combined with the Olink Target 48 Cytokine panel, it can detect up to 89 immune-related proteins using just 2μL of sample. The panel uses Olink’s PEA™ technology and offers precise, quantitative data, aiding research in immunology, immuno-oncology, and infectious diseases. It aims to reduce import barriers and is compatible with the Olink Signature Q100 benchtop system.
- Introduction of a new validated multiplexed protein assay panel.
- Capable of detecting and quantifying up to 44 biomarkers using only 1μL of sample.
- Combining with the Olink Target 48 Cytokine panel allows detection of up to 89 immune-related proteins using 2μL of sample.
- Utilizes Olink’s proven PEA™ technology for precise, quantitative data.
- Supports research in key therapeutic areas including inflammation, immune response, immuno-oncology, and infectious diseases.
- Aims to reduce import barriers and long lead-times in certain geographies.
- Fully compatible with the Olink Signature Q100 benchtop system, offering simplified workflows and minimal maintenance.
- No immediate financial impact or revenue projections mentioned.
- Potential high costs associated with the new technology and equipment.
- Unclear timelines for widespread adoption and integration into clinical settings.
Insights
Olink's new Target 48 Immune Surveillance panel represents a significant advancement in immuno-biomarker profiling. This multiplexed protein assay panel can quantify up to 44 biomarkers with just 1μL of sample. This efficiency is important for clinical research where sample volumes can be limited.
The ability to detect and quantify biomarkers related to inflammation, immune response, immuno-oncology and infectious diseases offers researchers a comprehensive tool for understanding complex biological pathways. Combining this panel with the Olink Target 48 Cytokine panel allows simultaneous detection of up to 89 immune-related proteins, further enhancing its utility.
Olink’s use of PEA™ technology ensures high fidelity and transparent quality control. These aspects are critical as they provide a level of data integrity that researchers can rely on for making informed decisions.
In the short term, this product is likely to accelerate research by providing more precise and reliable data. Long-term, it could lead to breakthroughs in precision medicine by identifying predictive biomarkers for various diseases, thus impacting future oncology trials significantly.
Retail investors should understand that while this technology is promising, its adoption in clinical settings will take time. The immediate impact will be seen in the acceleration of research, but commercialization and clinical application will be gradual.
The introduction of the Olink Target 48 Immune Surveillance panel highlights Olink Holding AB's commitment to innovation in the proteomics market. The panel's ability to reduce import barriers is particularly noteworthy. This feature will expedite international research collaborations and potentially expand Olink's market reach.
The compatibility with the Olink® Signature Q100 benchtop system simplifies workflows and reduces maintenance needs, which can be a significant selling point for research laboratories.
From a market perspective, Olink's new product could lead to increased sales and a stronger market position. The focus on precision medicine aligns well with current trends in personalized healthcare, making Olink a potentially attractive investment.
However, it is important to consider that the immediate financial impact might be limited as the product will first need to gain traction among researchers and clinicians. Investors should keep an eye on future earnings reports for signs of increased revenue from this segment.
The launch of Olink Target 48 Immune Surveillance exemplifies Olink Holding AB’s strategic push into advanced proteomics solutions. While direct financial results aren't immediately clear, the enhanced capabilities of this technology could lead to increased demand in the long run.
Given the panel's potential to accelerate research and its compatibility with existing systems, the revenue growth prospects look promising. Investors should watch for increased adoption rates and any associated sales growth in future financial statements.
In the short term, the stock might react positively due to the innovative nature of the product and its potential to open new revenue streams. Long-term investors should also consider this as a strategic move that aligns with the growing trend towards precision medicine, which may lead to sustained revenue growth.
However, investors should remain cautious as the commercial success of such specialized products can be unpredictable. The success will largely depend on how well it is adopted in the research community and eventually in clinical settings.
UPPSALA, Sweden, June 06, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced the introduction of Olink Target 48 Immune Surveillance, a validated multiplexed protein assay panel that offers a detailed view of the immune system for in-depth monitoring of inflammation and immune response in clinical research.
More Confidence, More Insights, Less Sample
Biomarker selection for Olink Target 48 Immune Surveillance were designed to give researchers the most effective platform for detecting and quantifying up to 44 well-established biomarkers across key immunological processes in as little as 1μL of sample. When combined with the Olink Target 48 Cytokine panel, scientists can simultaneously detect and quantify up to 89 immune-related proteins while still only using 2μL of sample. This represents a powerful new tool for identifying protein signatures across a range of important therapeutic areas including inflammation, immune response, immuno-oncology and infectious diseases.
Developed using Olink’s proven PEA™ technology, Olink Target 48 Immune Surveillance delivers complete confidence with transparent quality control. In addition to industry-leading internal quality control and validation, Olink works closely with the research community to further test, validate, and improve the performance of products.
Russell W. Jenkins, Assistant Professor, Center of Cancer Research at Broad Institute of MIT and Harvard stated, “With the Olink Target 48 Immune Surveillance and the Olink Target 48 Cytokine Panel we now have the ability to gain the precise, quantitative data we need for our most valued analytes to support data and scientific conclusions.“
Arnav Metha, Attending Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Malignancies at Massachusetts General Hospital Cancer Center shared, “The Olink Target 48 Immune Surveillance and Cytokine Panels will now allow us to more quantitatively dissect biological pathways and predictive biomarkers discovered from the Olink Explore panels. These targeted immune panels are a key step forward towards clinical utilization of these biomarkers in future oncology trials.”
Global Reach, Accelerated Research.
Olink Target 48 Immune Surveillance has been developed with the aim of reducing import barriers such as long lead-times for importing into geographies with blood or plasma-derived import licences. The Olink Target 48 Immune Surveillance is fully compatible with the Olink® Signature Q100 benchtop system, providing simplified workflows, minimal maintenance, and powerful QC and statistical analysis within the Olink NPX™ Signature Software, enabling laboratories to accelerate their research.
“It’s extremely exciting to consider the potential of the newest Olink Target 48 solution to yield predictive insights into therapeutic response or disease progression, moving us closer to realizing the promise of precision medicine.” said Carl Raimond, President of Olink.
The introduction of the Olink Target 48 Immune Surveillance panel adds to Olink`s broad portfolio of next-generation proteomics solutions. From discovery to translational applications, Olink provides industry-leading solutions encompassing all stages of drug development and disease characterization.
Learn more about Olink’s next-generation proteomics technologies at Olink.com.
Investor contact
David Deuchler, CFA
Gilmartin Group
olink@gilmartinir.com
Media contact
Michael B. Gonzales, PhD
Vice President, Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com
About Olink
Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major pharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America and Asia. Olink is headquartered in Uppsala, Sweden.
Forward-looking statements
This release may contain forward-looking statements within the meaning of applicable securities laws, including the U.S. Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Olink’s strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs as of the date hereof and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those related to Olink’s business, operations, supply chain, strategy, goals and anticipated timelines, including for the delivery of Olink Explore 3072 and the expansion of the Explore platform, competition, and other risks identified in the section entitled “Risk Factors” in Olink’s Registration Statement on Form F-1, as amended (File No. 333-253818) filed with the U.S. Securities and Exchange Commission (SEC) and in the other filings, reports, and documents Olink files with the SEC from time to time. Olink expressly disclaims any obligation to update any forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.
FAQ
What is the Olink Target 48 Immune Surveillance panel?
How many biomarkers can the Olink Target 48 Immune Surveillance panel detect?
What is the sample requirement for the Olink Target 48 Immune Surveillance panel?
How many proteins can be detected using the Olink Target 48 Immune Surveillance and Cytokine panels together?
What technology does the Olink Target 48 Immune Surveillance panel use?
What are the therapeutic areas supported by the Olink Target 48 Immune Surveillance panel?
Is the Olink Target 48 Immune Surveillance panel compatible with any specific system?
What are the benefits of the Olink Target 48 Immune Surveillance panel?
